DrugRepV Browse Page

DrugRepV browse page allows user to take a glance of the particular antiviral agent.Fields in the webpage is hylerlinked ot various external repositories like DrugBank, PubChem, Clinicaltrials.gov,and PubMed.User can explore the biological, Clinical, Chemical, and Structural details of every repurposed drug candidate.By clicking on the table header arrows, user can sort entries in ascending or descending order.


Total number of Records for Nervous System are 462

DrugRepV_ID	Antiviral Name	Drug type	Primary Indication	Secondary Indication	Strain	Pathways	Assay	Activity	Clinical Status	References
DrugRepV_0009	Sertraline Hydrochloride	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	Decrease (50 %)	Approved	29033372
DrugRepV_0013	Fluoxetine Hydrochloride	Nervous System	Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	No significant effect (40 %)	Approved, Vet approved	29033372
DrugRepV_0075	Bromocriptine	Nervous System	Parkinson disease	Zika virus	Puerto Rico strain PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	28185815
DrugRepV_0076	Bromocriptine	Nervous System	Parkinson disease	Zika virus	Puerto Rico strain PRVABC-59	NA	Real-time PCR	Decrease (4 Log viral titer (copies/ml))	Approved	28185815
DrugRepV_0077	Bromocriptine	Nervous System	Parkinson disease	Zika virus	Puerto Rico strain PRVABC-59	NA	Plaque assay	Decrease (>99 %)	Approved	28185815
DrugRepV_0200	Maprotiline	Nervous System	Bipolar depression	Ebola virus	VLP	NA	Immunoflourescence assay	Decrease (50 %)	Approved, Investigational	27890675
DrugRepV_0212	Maprotiline	Nervous System	Bipolar depression	Ebola virus	EBOLA/Mayinga-eGFP	NA	Immunoflourescence assay	Decrease (50 %)	Approved, Investigational	27890675
DrugRepV_0324	Benztropine	Nervous System	Parkinson disease	Ebola virus	EBOV-eGFP	NA	Immunoflourescence assay	Decrease (50 %)	Approved	27622822
DrugRepV_0330	Thiothixene	Nervous System	Schizophrenia	Ebola virus	EBOV-eGFP	NA	Immunoflourescence assay	Decrease (50 %)	Approved	27622822
DrugRepV_0331	Prochlorperazine	Nervous System	Nausea | Vomiting | Schizophrenia	Ebola virus	EBOV-eGFP	NA	Immunoflourescence assay	Decrease (50 %)	Approved, Vet approved	27622822
DrugRepV_0332	Fluphenazine	Nervous System	Psychosis	Ebola virus	EBOV-eGFP	NA	Immunoflourescence assay	Decrease (50 %)	Approved	27622822
DrugRepV_0333	Perphenazine	Nervous System	Psychosis | Nausea and vomiting in adults	Ebola virus	EBOV-eGFP	NA	Immunoflourescence assay	Decrease (50 %)	Approved	27622822
DrugRepV_0334	Promazine	Nervous System	Psychomotor agitation	Ebola virus	EBOV-eGFP	NA	Immunoflourescence assay	Decrease (50 %)	Approved, Vet approved	27622822
DrugRepV_0335	Paroxetine	Nervous System	Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD)	Ebola virus	EBOV-eGFP	NA	Immunoflourescence assay	Decrease (50 %)	Approved, Investigational	27622822
DrugRepV_0344	Benztropine	Nervous System	Parkinson disease	Ebola virus	Ebola Zaire glycoprotein pseudotype vesicular stomatitis virus	NA	Renilla luciferase assay	Decrease (50 %)	Approved	27622822
DrugRepV_0350	Prochlorperazine	Nervous System	Nausea | Vomiting | Schizophrenia	Ebola virus	Ebola Zaire glycoprotein pseudotype vesicular stomatitis virus	NA	Renilla luciferase assay	Decrease (50 %)	Approved	27622822
DrugRepV_0351	Paroxetine	Nervous System	Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD)	Ebola virus	Ebola Zaire glycoprotein pseudotype vesicular stomatitis virus	NA	Renilla luciferase assay	Decrease (50 %)	Approved, Investigational	27622822
DrugRepV_0361	Prochlorperazine	Nervous System	Nausea | Vomiting | Schizophrenia	Ebola virus	Ebola Zaire	NA	Survival assay	No significant effect	Approved	27622822
DrugRepV_0362	Benztropine	Nervous System	Parkinson disease	Ebola virus	Ebola Zaire	NA	Survival assay	No significant effect	Approved	27622822
DrugRepV_0363	Benztropine	Nervous System	Parkinson disease	Ebola virus	Ebola Zaire	NA	Survival assay	No significant effect	Approved	27622822
DrugRepV_0370	Benztropine Mesylate	Nervous System	Parkinson disease	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0377	Clomipramine Hydrochloride	Nervous System	Obsessive-compulsive disorder	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0385	Fluphenazine Hydrochloride	Nervous System	Psychosis	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0392	Maprotiline Hydrochloride	Nervous System	Bipolar depression	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0399	Paroxetine Hydrochloride Hemihydrate	Nervous System	Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD)	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0402	Perphenazine	Nervous System	Psychosis | Nausea and vomiting in adults	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0404	Prochlorperazine Edisylate	Nervous System	Nausea | Vomiting | Schizophrenia	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Vet approved	26041706
DrugRepV_0409	Sertraline Hydrochloride	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0414	Thioridazine Hydrochloride	Nervous System	Schizophrenia | Anxiety disorder	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Withdrawn	26041706
DrugRepV_0418	Trifluoperazine Hydrochloride	Nervous System	Schizophrenia and other psychotic disorders	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0419	Triflupromazine Hydrochloride	Nervous System	Psychosis	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0421	Aripiprazole	Nervous System	Schizophrenia	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0425	Benztropine	Nervous System	Parkinson disease	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0429	Clomipramine	Nervous System	Depression, schizophrenia, Tourette disorder	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0432	Flupentixol	Nervous System	Schizophrenia | Depression	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational, Withdrawn	26041706
DrugRepV_0433	Fluphenazine	Nervous System	Psychosis	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0436	Maprotiline	Nervous System	Bipolar depression	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0437	Paroxetine	Nervous System	Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD)	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0438	Pimozide	Nervous System	Tourette Disorder	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0440	Prochlorperazine	Nervous System	Nausea | Vomiting | Schizophrenia	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0442	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0447	Thioridazine	Nervous System	Schizophrenia | Anxiety disorder	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Withdrawn	26041706
DrugRepV_0449	Aripiprazole	Nervous System	Schizophrenia	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0452	Benztropine	Nervous System	Parkinson disease	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0456	Clomipramine	Nervous System	Depression, schizophrenia, Tourette disorder	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0459	Flupentixol	Nervous System	Schizophrenia | Depression	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational, Withdrawn	26041706
DrugRepV_0460	Fluphenazine	Nervous System	Psychosis	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0463	Maprotiline	Nervous System	Bipolar depression	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0465	Paroxetine	Nervous System	Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD)	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0466	Pimozide	Nervous System	Tourette Disorder	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0468	Prochlorperazine	Nervous System	Nausea | Vomiting | Schizophrenia	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0470	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0474	Thioridazine	Nervous System	Schizophrenia | Anxiety disorder	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Withdrawn	26041706
DrugRepV_0477	Aripiprazole	Nervous System	Schizophrenia	Ebola virus	EBOV-VLP	NA	Flow cytometry	Decrease (>90 %)	Approved	26041706
DrugRepV_0481	Benztropine	Nervous System	Parkinson disease	Ebola virus	EBOV-VLP	NA	Flow cytometry	Decrease (>90 %)	Approved	26041706
DrugRepV_0485	Clomipramine	Nervous System	Depression, schizophrenia, Tourette disorder	Ebola virus	EBOV-VLP	NA	Flow cytometry	Decrease (>90 %)	Approved	26041706
DrugRepV_0488	Flupentixol	Nervous System	Schizophrenia | Depression	Ebola virus	EBOV-VLP	NA	Flow cytometry	Decrease (>90 %)	Approved, Investigational, Withdrawn	26041706
DrugRepV_0489	Fluphenazine	Nervous System	Psychosis	Ebola virus	EBOV-VLP	NA	Flow cytometry	Decrease (>90 %)	Approved	26041706
DrugRepV_0492	Maprotiline	Nervous System	Bipolar depression	Ebola virus	EBOV-VLP	NA	Flow cytometry	Decrease (>90 %)	Approved, Investigational	26041706
DrugRepV_0494	Paroxetine	Nervous System	Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD)	Ebola virus	EBOV-VLP	NA	Flow cytometry	Decrease (>90 %)	Approved, Investigational	26041706
DrugRepV_0495	Pimozide	Nervous System	Tourette Disorder	Ebola virus	EBOV-VLP	NA	Flow cytometry	Decrease (>90 %)	Approved	26041706
DrugRepV_0497	Prochlorperazine	Nervous System	Nausea | Vomiting | Schizophrenia	Ebola virus	EBOV-VLP	NA	Flow cytometry	Decrease (>90 %)	Approved	26041706
DrugRepV_0499	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Ebola virus	EBOV-VLP	NA	Flow cytometry	Decrease (>90 %)	Approved	26041706
DrugRepV_0504	Thioridazine	Nervous System	Schizophrenia | Anxiety disorder	Ebola virus	EBOV-VLP	NA	Flow cytometry	Decrease (>90 %)	Approved, Withdrawn	26041706
DrugRepV_0508	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Ebola virus	ma-EBOV	NA	Survival assay	Increase	Approved	26041706
DrugRepV_0513	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Ebola virus	EBOV/Kik	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0514	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Ebola virus	EBOV/May	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0515	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Ebola virus	SUDV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0516	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Ebola virus	MARV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0517	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Ebola virus	RAVV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0529	Thiothixene	Nervous System	Schizophrenia	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0531	Maprotiline	Nervous System	Bipolar depression	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26038505
DrugRepV_0533	Benztropine	Nervous System	Parkinson disease	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0536	Trifluoperazine	Nervous System	Schizophrenia and other psychotic disorders	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0539	Clomipramine	Nervous System	Depressive disorder	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0549	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0555	Thioproperazine	Nervous System	Psychosis | Acute and Chronic schizophrenia	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0560	Bifemelane	Nervous System	Depressive disorder	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Experimental	26038505
DrugRepV_0571	Imipramine	Nervous System	Depression	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0577	Chlorpromazine	Nervous System	Schizophrenia	Crimean-Congo hemorrhagic fever virus	IbAr10200, Nigeria	NA	Plaque assay	Decrease (50 %)	Approved	25796972
DrugRepV_0578	Chlorpromazine	Nervous System	Schizophrenia	Crimean-Congo hemorrhagic fever virus	ArD39554	NA	Plaque assay	Decrease (50 %)	Approved	25796972
DrugRepV_0579	Chlorpromazine	Nervous System	Schizophrenia	Crimean-Congo hemorrhagic fever virus	IbAr10200, Nigeria	NA	Plaque assay	Decrease (50 %)	Approved	25796972
DrugRepV_0607	Biperiden	Nervous System	Parkinson disease	Lassa virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (27 %)	Approved	23577127
DrugRepV_0611	Dibucaine	Nervous System	Anesthesia	Lassa virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (49 %)	Approved	23577127
DrugRepV_0618	Fluoxetine	Nervous System	Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia	Lassa virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (76 %)	Approved, Vet approved	23577127
DrugRepV_0623	Paroxetine	Nervous System	Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD)	Lassa virus	GP derived Pseudovirus	NA	Luciferase reporter assay	No significant effect (6 %)	Approved, Investigational	23577127
DrugRepV_0625	Prochlorperazine	Nervous System	Nausea | Vomiting | Schizophrenia	Lassa virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (70 %)	Approved	23577127
DrugRepV_0626	Protriptyline	Nervous System	Depressive disorder	Lassa virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (28 %)	Approved	23577127
DrugRepV_0628	Trihexyphenidyl	Nervous System	Parkinson Disease	Lassa virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (52 %)	Approved	23577127
DrugRepV_0630	Biperiden	Nervous System	Parkinson disease	Lassa virus	Josiah	NA	Real-time PCR	No significant effect	Approved	23577127
DrugRepV_0638	Fluoxetine	Nervous System	Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia	Lassa virus	Josiah	NA	Real-time PCR	No significant effect	Approved, Vet approved	23577127
DrugRepV_0642	Paroxetine	Nervous System	Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD)	Lassa virus	Josiah	NA	Real-time PCR	No significant effect	Approved, Investigational	23577127
DrugRepV_0643	Trihexyphenidyl	Nervous System	Parkinson Disease	Lassa virus	Josiah	NA	Real-time PCR	No significant effect	Approved	23577127
DrugRepV_0646	Biperiden	Nervous System	Parkinson disease	Marburg virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (89 %)	Approved	23577127
DrugRepV_0650	Dibucaine	Nervous System	Anesthesia	Marburg virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (93 %)	Approved	23577127
DrugRepV_0657	Fluoxetine	Nervous System	Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia	Marburg virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (98 %)	Approved, Vet approved	23577127
DrugRepV_0662	Paroxetine	Nervous System	Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD)	Marburg virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (89 %)	Approved, Investigational	23577127
DrugRepV_0664	Prochlorperazine	Nervous System	Nausea | Vomiting | Schizophrenia	Marburg virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (93 %)	Approved	23577127
DrugRepV_0665	Protriptyline	Nervous System	Depressive disorder	Marburg virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (80 %)	Approved	23577127
DrugRepV_0667	Trihexyphenidyl	Nervous System	Parkinson Disease	Marburg virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (91 %)	Approved	23577127
DrugRepV_0670	Biperiden	Nervous System	Parkinson disease	Ebola virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (98 %)	Approved	23577127
DrugRepV_0674	Dibucaine	Nervous System	Anesthesia	Ebola virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (99 %)	Approved	23577127
DrugRepV_0681	Fluoxetine	Nervous System	Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia	Ebola virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (96 %)	Approved, Vet approved	23577127
DrugRepV_0686	Paroxetine	Nervous System	Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD)	Ebola virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (98 %)	Approved, Investigational	23577127
DrugRepV_0688	Prochlorperazine	Nervous System	Nausea | Vomiting | Schizophrenia	Ebola virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (95 %)	Approved	23577127
DrugRepV_0689	Protriptyline	Nervous System	Depressive disorder	Ebola virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (83 %)	Approved	23577127
DrugRepV_0691	Trihexyphenidyl	Nervous System	Parkinson Disease	Ebola virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (97 %)	Approved	23577127
DrugRepV_0693	Biperiden	Nervous System	Parkinson disease	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	No significant effect	Approved	23577127
DrugRepV_0696	Dibucaine	Nervous System	Anesthesia	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	No significant effect	Approved	23577127
DrugRepV_0703	Fluoxetine	Nervous System	Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	No significant effect	Approved, Vet approved	23577127
DrugRepV_0707	Paroxetine	Nervous System	Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD)	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	No significant effect	Approved, Investigational	23577127
DrugRepV_0708	Trihexyphenidyl	Nervous System	Parkinson Disease	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	No significant effect	Approved	23577127
DrugRepV_0725	Prochlorperazine	Nervous System	Nausea | Vomiting | Schizophrenia	Ebola virus	ma-EBOV	NA	NA	No significant effect	Approved	23577127
DrugRepV_0730	Fluoxetine	Nervous System	Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia	Ebola virus	ma-EBOV	NA	NA	No significant effect	Approved, Vet approved	23577127
DrugRepV_0780	Sertraline Hydrochloride	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (89 %)	Approved	27476412
DrugRepV_0786	Trifluoperazine Hydrochloride	Nervous System	Schizophrenia and other psychotic disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (70.37 %)	Approved	27476412
DrugRepV_0793	Pimozide	Nervous System	Tourette Disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (72.91 %)	Approved	27476412
DrugRepV_0794	Thioridazine Hydrochloride	Nervous System	Schizophrenia | Anxiety disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (69.315 %)	Approved, Withdrawn	27476412
DrugRepV_0806	Paroxetine Hydrochloride	Nervous System	Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (58.91 %)	Approved, Investigational	27476412
DrugRepV_0826	Risperidone	Nervous System	Schizophrenia | Mood disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (63.025 %)	Approved, Investigational	27476412
DrugRepV_0835	Tolcapone	Nervous System	Parkinson's Disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (60.86 %)	Approved, Withdrawn	27476412
DrugRepV_0840	Zaleplon	Nervous System	Insomnia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.615 %)	Approved	27476412
DrugRepV_0868	Bromocriptine Mesylate	Nervous System	Parkinson disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (61.805 %)	Approved	27476412
DrugRepV_0869	Donepezil Hydrochloride	Nervous System	Dementia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.885 %)	Approved	27476412
DrugRepV_0874	Nortriptyline Hydrochloride	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.8 %)	Approved	27476412
DrugRepV_0879	Ziprasidone Hydrochloride	Nervous System	Schizophrenia and psychotic disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.475 %)	Approved	27476412
DrugRepV_0880	Fluphenazine Hydrochloride	Nervous System	Psychosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (56.715 %)	Approved	27476412
DrugRepV_0887	Trazodone Hydrochloride	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.415 %)	Approved, Investigational	27476412
DrugRepV_0892	Naltrexone Hydrochloride	Nervous System	Alcohol dependence	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (59.515 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_0895	Nefazodone Hydrochloride	Nervous System	Depression	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.595 %)	Approved, Withdrawn	27476412
DrugRepV_0900	Tetrabenazine	Nervous System	Huntington disease | Hemiballismus | Senile chorea | Tourette syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (56.175 %)	Approved	27476412
DrugRepV_0910	Tacrine Hydrochloride	Nervous System	Dementia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (57.39 %)	Approved	27476412
DrugRepV_0922	Oxcarbazepine	Nervous System	Partial seizures	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.92 %)	Approved	27476412
DrugRepV_0925	Duloxetine Hydrochloride	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.7 %)	Approved	27476412
DrugRepV_0929	Methacholine Chloride	Nervous System	Bronchial hyperreactivity	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.51 %)	Approved, Investigational	27476412
DrugRepV_0930	Apomorphine Hydrochloride Hemihydrate	Nervous System	Parkinson's disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (57.305 %)	Approved	27476412
DrugRepV_0932	Almotriptan	Nervous System	Acute migraine	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.88 %)	Approved	27476412
DrugRepV_0933	Felbamate	Nervous System	Epilepsy	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.745 %)	Approved	27476412
DrugRepV_0935	Lamotrigine	Nervous System	Epilepsy and bipolar disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.015 %)	Approved, Investigational	27476412
DrugRepV_0940	Acetaminophen	Nervous System	Fever, minor aches and pains	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.27 %)	Approved	27476412
DrugRepV_0943	Varenicline Tartrate	Nervous System	Nicotine dependence	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.14 %)	Approved	27476412
DrugRepV_0951	Bupropion	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.045 %)	Approved	27476412
DrugRepV_0956	Valproate Sodium	Nervous System	NA	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.71 %)	Approved	27476412
DrugRepV_0957	Primidone	Nervous System	Epilepsy	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.36 %)	Approved, Vet approved	27476412
DrugRepV_0959	Eszopiclone	Nervous System	Insomnia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.415 %)	Approved	27476412
DrugRepV_0960	Haloperidol	Nervous System	Schizophrenia | Psychotic disorders | Chemotherapy-induced nausea/vomiting	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (57.42 %)	Approved	27476412
DrugRepV_0971	Iloperidone	Nervous System	Schizophrenia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (56.515 %)	Approved	27476412
DrugRepV_0972	Etomidate	Nervous System	General anesthesia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.365 %)	Approved	27476412
DrugRepV_0973	Zonisamide	Nervous System	Epilepsy	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.085 %)	Approved	27476412
DrugRepV_0976	Phenytoin	Nervous System	Seizures	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.54 %)	Approved, Vet approved	27476412
DrugRepV_0977	Mirtazapine	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.19 %)	Approved	27476412
DrugRepV_0983	Buspirone Hydrochloride	Nervous System	Anxiety and depression	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.19 %)	Approved	27476412
DrugRepV_0988	Pyridostigmine Bromide	Nervous System	Myasthenia gravis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.965 %)	Approved, Investigational	27476412
DrugRepV_0998	Carbamazepine	Nervous System	Epilepsy and pain	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.68 %)	Approved	27476412
DrugRepV_1007	Phenelzine Sulfate	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.225 %)	Approved	27476412
DrugRepV_1008	Disulfiram	Nervous System	Chronic alcoholism	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.105 %)	Approved	27476412
DrugRepV_1018	Caffeine	Nervous System	Fatigue, orthostatic hypotension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.37 %)	Approved	27476412
DrugRepV_1034	Lacosamide	Nervous System	Epilepsy	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.055 %)	Approved	27476412
DrugRepV_1038	Rasagiline Mesylate	Nervous System	Idiopathic Parkinson's disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.31 %)	Approved	27476412
DrugRepV_1042	Ergotamine Tartrate	Nervous System	Vascular headache	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (56.33 %)	Approved	27476412
DrugRepV_1046	Rivastigmine Tartrate	Nervous System	Dementia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.655 %)	Approved, Investigational	27476412
DrugRepV_1051	Bupivacaine Hydrochloride	Nervous System	Anesthesia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.995 %)	Approved	27476412
DrugRepV_1056	Ethosuximide	Nervous System	Epilepsy	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.245 %)	Approved	27476412
DrugRepV_1059	Mepivacaine Hydrochloride	Nervous System	Analgesia | Anesthesia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.64 %)	Approved, Vet approved	27476412
DrugRepV_1062	Acamprosate	Nervous System	Alcohol dependence	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.895 %)	Approved	27476412
DrugRepV_1069	Aripiprazole	Nervous System	Schizophrenia and psychotic disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.35 %)	Approved	27476412
DrugRepV_1074	Riluzole Hydrochloride	Nervous System	Amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (58.545 %)	Approved, Investigational	27476412
DrugRepV_1098	Entacapone	Nervous System	Parkinson Disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.01 %)	Approved	27476412
DrugRepV_1106	Quetiapine Fumarate	Nervous System	Schizophrenia | Bipolar disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.45 %)	Approved	27476412
DrugRepV_1108	Trimethadione	Nervous System	Seizure | Epilepsy	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.375 %)	Approved	27476412
DrugRepV_1112	Capsaicin	Nervous System	Neuropathic pain associated with post-herpetic neuralgia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.63 %)	Approved	27476412
DrugRepV_1122	Vigabatrin	Nervous System	Epilepsy and Seizure	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.795 %)	Approved	27476412
DrugRepV_1126	Milnacipran Hydrochloride	Nervous System	Depressive disorder | Fibromyalgia pain	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.375 %)	Approved, Investigational	27476412
DrugRepV_1127	Droperidol	Nervous System	Nausea and vomiting	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.61 %)	Approved	27476412
DrugRepV_1128	Ramelteon	Nervous System	Insomnia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.02 %)	Approved, Investigational	27476412
DrugRepV_1140	Clozapine	Nervous System	Psychosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.96 %)	Approved	27476412
DrugRepV_1150	Diflunisal	Nervous System	Osteoarthritis and rheumatoid arthritis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.05 %)	Approved	27476412
DrugRepV_1164	Memantine Hydrochloride	Nervous System	Alzheimer's dementia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.785 %)	Approved, Investigational	27476412
DrugRepV_1168	Ropivacaine Hydrochloride Monohydrate	Nervous System	Used in obstetric anesthesia and regional anesthesia for surgery	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.655 %)	Approved	27476412
DrugRepV_1174	Chlorpromazine Hydrochloride	Nervous System	Schizophrenia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.955 %)	Approved	27476412
DrugRepV_1175	Nicotine	Nervous System	Nicotine dependence (Tobacco smoke)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.33 %)	Approved	27476412
DrugRepV_1180	Topiramate	Nervous System	Seizures (Epilepsy) | Migraine	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.995 %)	Approved	27476412
DrugRepV_1184	Propofol	Nervous System	Anaesthesia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.53 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_1195	Dalfampridine	Nervous System	Multiple sclerosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.235 %)	Approved	27476412
DrugRepV_1197	Tiagabine Hydrochloride	Nervous System	Panic disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.68 %)	Approved, Investigational	27476412
DrugRepV_1198	Trihexyphenidyl Hydrochloride	Nervous System	Parkinson Disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.61 %)	Approved	27476412
DrugRepV_1200	Fosphenytoin Sodium Pentahydrate	Nervous System	NA	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.9 %)	Approved, Investigational	27476412
DrugRepV_1217	Clomipramine Hydrochloride	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.19 %)	Approved	27476412
DrugRepV_1229	Nalbuphine Hydrochloride Dihydrate	Nervous System	Pain	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.375 %)	Approved	27476412
DrugRepV_1253	Dihydroergotamine Mesylate	Nervous System	Migraine disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.92 %)	Approved	27476412
DrugRepV_1258	Ropinirole Hydrochloride	Nervous System	Parkinson's disease | Restless legs syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.565 %)	Approved, Investigational	27476412
DrugRepV_1267	Selegiline Hydrochloride	Nervous System	Parkinson's Disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.86 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_1275	Citalopram Hydrobromide	Nervous System	Depressive disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.045 %)	Approved	27476412
DrugRepV_1277	Naratriptan Hydrochloride	Nervous System	Migraine disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.13 %)	Approved, Investigational	27476412
DrugRepV_1283	Zolmitriptan	Nervous System	Migraine with or without auras	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.49 %)	Approved	27476412
DrugRepV_1284	Perphenazine	Nervous System	Psychosis | Nausea and vomiting in adults	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.76 %)	Approved	27476412
DrugRepV_1291	Olanzapine	Nervous System	Schizophrenia | Bipolar I disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.535 %)	Approved, Investigational	27476412
DrugRepV_1294	Pramipexole Dihydrochloride Monohydrate	Nervous System	Parkinson's disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.46 %)	Approved, Investigational	27476412
DrugRepV_1300	Paliperidone	Nervous System	Schizophrenia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.455 %)	Approved	27476412
DrugRepV_1324	Maprotiline Hydrochloride	Nervous System	Bipolar depression	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.58 %)	Approved, Investigational	27476412
DrugRepV_1343	Articaine Hydrochloride	Nervous System	Anaesthesia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.825 %)	Approved	27476412
DrugRepV_1344	Amantadine Hydrochloride	Nervous System	Influenza and Parkinson Disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.43 %)	Approved	27476412
DrugRepV_1357	Desvenlafaxine Succinate Hydrate	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.305 %)	Approved	27476412
DrugRepV_1367	Dexmedetomidine Hydrochloride	Nervous System	Sedative therapy, pain relief , anxiety reduction and analgesia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.065 %)	Approved	27476412
DrugRepV_1370	Sumatriptan Succinate	Nervous System	Migraine disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.465 %)	Approved, Investigational	27476412
DrugRepV_1372	Tranylcypromine Hemisulfate	Nervous System	Depressive episode without melancholia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.615 %)	Approved, Investigational	27476412
DrugRepV_1374	Gabapentin	Nervous System	Epilepsy (seizure)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.8 %)	Approved	27476412
DrugRepV_1384	Hydroxyzine Dihydrochloride	Nervous System	Anxiety | Tension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.005 %)	Approved	27476412
DrugRepV_1398	Trimipramine Maleate	Nervous System	Anxiety, Agitation or Sleep disturbance	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (40.4 %)	Approved	27476412
DrugRepV_1421	Tramadol Hydrochloride	Nervous System	Pain	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.36 %)	Approved, Investigational	27476412
DrugRepV_1424	Levetiracetam	Nervous System	Epilepsy	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.66 %)	Approved, Investigational	27476412
DrugRepV_1428	Rufinamide	Nervous System	Seizure disorder :- Lennox-Gastuat syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.69 %)	Approved	27476412
DrugRepV_1431	Biperiden Hydrochloride	Nervous System	Parkinson disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (41.17 %)	Approved	27476412
DrugRepV_1435	Imipramine Hydrochloride	Nervous System	Depression	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.665 %)	Approved	27476412
DrugRepV_1443	Amoxapine	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.49 %)	Approved	27476412
DrugRepV_1447	Escitalopram	Nervous System	Major depressive disorder and generalized anxiety disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.27 %)	Approved	27476412
DrugRepV_1449	Bethanechol Chloride	Nervous System	Neurogenic bladder dysfunction	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.03 %)	Approved	27476412
DrugRepV_1452	Doxepin Hydrochloride	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (40.49 %)	Approved	27476412
DrugRepV_1459	Asenapine Maleate	Nervous System	Psychosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (39.345 %)	Approved	27476412
DrugRepV_1461	Benztropine Mesylate	Nervous System	Parkinson disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (41.365 %)	Approved	27476412
DrugRepV_1465	Protriptyline Hydrochloride	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (37.31 %)	Approved	27476412
DrugRepV_1474	Isocarboxazid	Nervous System	Depression	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.14 %)	Approved	27476412
DrugRepV_1484	Fluvoxamine Maleate	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (37.14 %)	Approved, Investigational	27476412
DrugRepV_1488	Venlafaxine Hydrochloride	Nervous System	Depression | General anxiety disorder | Social phobia | Panic disorder | vasomotor symptoms	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.34 %)	Approved	27476412
DrugRepV_1489	Atomoxetine Hydrochloride	Nervous System	Attention-deficit hyperactivity disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (37.265 %)	Approved	27476412
DrugRepV_1492	Desipramine Hydrochloride	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (37.2 %)	Approved	27476412
DrugRepV_1509	Fluoxetine Hydrochloride	Nervous System	Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (31.79 %)	Approved, Vet approved	27476412
DrugRepV_1510	Amitriptyline Hydrochloride	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (37.4 %)	Approved	27476412
DrugRepV_1513	Loxapine succinate	Nervous System	Schizophrenia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (34.465 %)	Approved	27476412
DrugRepV_1538	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Zika virus	MEX_I_7	NA	Flow cytometry	No significant effect (50 %)	Approved	27476412
DrugRepV_1552	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Zika virus	DAK_41525	NA	Flow cytometry	Increase (120 %)	Approved	27476412
DrugRepV_1561	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50 %)	Approved	27476412
DrugRepV_1581	Maprotiline Hydrochloride	Nervous System	Bipolar depression	Rift Valley fever virus	MP12-Luc	NA	Luciferase reporter assay	Decrease (41 %)	Approved, Investigational	26217313
DrugRepV_1582	Quetiapine Fumarate	Nervous System	Schizophrenia | Bipolar disorder	Rift Valley fever virus	MP12-Luc	NA	Luciferase reporter assay	Decrease (41 %)	Approved	26217313
DrugRepV_1621	Naltrexone	Nervous System	Alcohol dependence	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	Approved, Investigational, Vet approved	24991006
DrugRepV_1979	Benztropine Mesylate	Nervous System	Parkinson disease	Middle East respiratory syndrome coronavirus	Jordan	NA	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved	24841273
DrugRepV_1980	Fluspirilene	Nervous System	Schizophrenia	Middle East respiratory syndrome coronavirus	Jordan	NA	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved, Investigational	24841273
DrugRepV_1981	Thiothixene	Nervous System	Schizophrenia	Middle East respiratory syndrome coronavirus	Jordan	NA	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved	24841273
DrugRepV_1982	Fluphenazine Hydrochloride	Nervous System	Psychosis	Middle East respiratory syndrome coronavirus	Jordan	NA	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved	24841273
DrugRepV_1986	Chlorpromazine Hydrochloride	Nervous System	Psychosis	Middle East respiratory syndrome coronavirus	Jordan	NA	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved	24841273
DrugRepV_1988	Triflupromazine Hydrochloride	Nervous System	Psychosis	Middle East respiratory syndrome coronavirus	Jordan	NA	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved	24841273
DrugRepV_1989	Clomipramine Hydrochloride	Nervous System	Psychosis	Middle East respiratory syndrome coronavirus	Jordan	NA	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved	24841273
DrugRepV_2003	Benztropine Mesylate	Nervous System	Parkinson disease	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	24841273
DrugRepV_2004	Fluspirilene	Nervous System	Schizophrenia	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved, Investigational	24841273
DrugRepV_2005	Thiothixene	Nervous System	Schizophrenia	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	24841273
DrugRepV_2006	Fluphenazine Hydrochloride	Nervous System	Psychosis	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	24841273
DrugRepV_2010	Chlorpromazine Hydrochloride	Nervous System	Psychosis	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	24841273
DrugRepV_2011	Triflupromazine Hydrochloride	Nervous System	Psychosis	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	24841273
DrugRepV_2012	Clomipramine Hydrochloride	Nervous System	Psychosis	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	24841273
DrugRepV_2019	Paroxetine	Nervous System	Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD)	Ebola virus	Zaire strain-pEBOV	NA	Firefly luciferase assay	Decrease (50 %)	Approved, Investigational	26585243
DrugRepV_2023	Glafenine	Nervous System	Inflammatory disease	Ebola virus	Zaire strain-pEBOV	NA	Firefly luciferase assay	Decrease (50 %)	NA	26585243
DrugRepV_2036	Chlorpromazine	Nervous System	Schizophrenia	Middle East respiratory syndrome coronavirus	EMC/2012	NA	Cell viability assay	Decrease (50 %)	Approved	24841269
DrugRepV_2040	Chlorpromazine	Nervous System	Schizophrenia	Severe acute respiratory syndrome coronavirus	NA	NA	Cell viability assay	Decrease (50 %)	Approved	24841269
DrugRepV_2044	Chlorpromazine	Nervous System	Schizophrenia	Severe acute respiratory syndrome coronavirus	229E-GFP	NA	Cell viability assay	Decrease (50 %)	Approved	24841269
DrugRepV_2048	Fluoxetine Hydrochloride	Nervous System	Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia	Middle East respiratory syndrome coronavirus	EMC/2012	NA	Cell viability assay	Decrease (50 %)	Approved, Vet approved	24841269
DrugRepV_2087	Orphenadrine	Nervous System	Parkinson's disease | Muscle spasm	Ebola virus	HIV/EBOV	NA	Luciferase reporter assay	Decrease (50 %)	Approved	29981374
DrugRepV_2088	Orphenadrine	Nervous System	Parkinson's disease | Muscle spasm	Marburg virus	HIV/MARV	NA	Luciferase reporter assay	Decrease (50 %)	Approved	29981374
DrugRepV_2095	Hydroxyzine	Nervous System	Anxiety | Tension	Ebola virus	HIV/EBOV	NA	Luciferase reporter assay	Decrease (50 %)	Approved	29981374
DrugRepV_2096	Hydroxyzine	Nervous System	Anxiety | Tension	Marburg virus	HIV/MARV	NA	Luciferase reporter assay	Decrease (50 %)	Approved	29981374
DrugRepV_2176	Pizotifen Malate	Nervous System	Migraines	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (16.7563948 %)	Approved	27742486
DrugRepV_2190	Neostigmine Bromide	Nervous System	Myasthenia gravis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (11.3329876 %)	Approved	27742486
DrugRepV_2192	Ziprasidone Hydrochloride	Nervous System	Schizophrenia and psychotic disorders	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (10.899998 %)	Approved	27742486
DrugRepV_2195	Fluoxetine Hydrochloride	Nervous System	Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (10.4504102 %)	Approved, Vet approved	27742486
DrugRepV_2197	Olanzapine	Nervous System	Schizophrenia | Bipolar I disorder	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (10.0723372 %)	Approved, Investigational	27742486
DrugRepV_2229	Clozapine	Nervous System	Psychosis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (7.00172882 %)	Approved	27742486
DrugRepV_2236	Mianserin Hydrochloride	Nervous System	Depression	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (6.5508974 %)	Approved, Investigational	27742486
DrugRepV_2242	Asenapine	Nervous System	Psychosis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (6.19909164 %)	Approved	27742486
DrugRepV_2252	Phenytoin	Nervous System	Seizures	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (5.83857713 %)	Approved, Vet approved	27742486
DrugRepV_2262	Primidone	Nervous System	Epilepsy	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (5.34861552 %)	Approved, Vet approved	27742486
DrugRepV_2281	Antipyrine	Nervous System	Analgesic	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.7739269 %)	Approved	27742486
DrugRepV_2287	Iloperidone	Nervous System	Schizophrenia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.68190957 %)	Approved	27742486
DrugRepV_2293	Mepivacaine Hydrochloride	Nervous System	Analgesia | Anesthesia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.51844444 %)	Approved, Vet approved	27742486
DrugRepV_2295	Haloperidol	Nervous System	Schizophrenia | Psychotic disorders | Chemotherapy-induced nausea/vomiting	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.44529073 %)	Approved	27742486
DrugRepV_2297	Tianeptine Sodium	Nervous System	Depressive disorder | Irritable bowel syndrome (IBS)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.41872904 %)	Investigational	27742486
DrugRepV_2303	Aniracetam	Nervous System	Psychosis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.38872845 %)	Experimental	27742486
DrugRepV_2309	Vinpocetine	Nervous System	Epilepsy	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.10031537 %)	Investigational	27742486
DrugRepV_2315	Memantine Hydrochloride	Nervous System	Alzheimer's dementia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.94665072 %)	Approved, Investigational	27742486
DrugRepV_2316	Etomidate	Nervous System	General anesthesia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.92770767 %)	Approved	27742486
DrugRepV_2326	Dyclonine Hydrochloride	Nervous System	Anesthesia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.70472644 %)	Approved	27742486
DrugRepV_2331	Milnacipran Hydrochloride	Nervous System	Depressive disorder | Fibromyalgia pain	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.63202363 %)	Approved, Investigational	27742486
DrugRepV_2345	Meptazinol Hydrochloride	Nervous System	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.28059603 %)	Experimental	27742486
DrugRepV_2361	Quetiapine Fumarate	Nervous System	Schizophrenia | Bipolar disorder	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.90178299 %)	Approved	27742486
DrugRepV_2365	Benztropine Mesylate	Nervous System	Parkinson disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.84775979 %)	Approved	27742486
DrugRepV_2369	Duloxetine Hydrochloride	Nervous System	Depressive disorder	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.74588077 %)	Approved	27742486
DrugRepV_2410	Clomipramine Hydrochloride	Nervous System	Depressive disorder	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.09263056 %)	Approved	27742486
DrugRepV_2413	Entacapone	Nervous System	Parkinson Disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.96747673 %)	Approved	27742486
DrugRepV_2414	Flunarizine Dihydrochloride	Nervous System	Migraine | Vertigo | Epilepsy	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.96747673 %)	Approved	27742486
DrugRepV_2427	Chlorprothixene	Nervous System	Psychosis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.68794785 %)	Approved	27742486
DrugRepV_2429	Fluvoxamine Maleate	Nervous System	Depressive disorder	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.66473263 %)	Approved, Investigational	27742486
DrugRepV_2432	Trazodone Hydrochloride	Nervous System	Depressive disorder	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.62662677 %)	Approved, Investigational	27742486
DrugRepV_2489	Amfebutamone	Nervous System	Depression	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.27113824 %)	Approved	27742486
DrugRepV_2495	Ramelteon	Nervous System	Insomnia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.19581857 %)	Approved, Investigational	27742486
DrugRepV_2499	Donepezil Hydrochloride	Nervous System	Dementia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.11302961 %)	Approved	27742486
DrugRepV_2522	Pyridostigmine bromide	Nervous System	Myasthenia gravis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.333684 %)	Approved, Investigational	27742486
DrugRepV_2537	Naltrexone Hydrochloride	Nervous System	Alcohol dependence	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.6142901 %)	Approved, Investigational, Vet approved	27742486
DrugRepV_2541	Disulfiram	Nervous System	Chronic alcoholism	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.6684287 %)	Approved	27742486
DrugRepV_2548	Sodium salicylate	Nervous System	Acne | Psoriasis | Callouses | Corns Keratosis pilaris | Warts	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.8129041 %)	Approved	27742486
DrugRepV_2561	Mirtazapine	Nervous System	Depressive disorder	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.0396288 %)	Approved	27742486
DrugRepV_2593	Articaine Hydrochloride	Nervous System	Anaesthesia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.4948978 %)	Approved	27742486
DrugRepV_2601	Phenacetin	Nervous System	Analgesic	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.5882537 %)	Withdrawn	27742486
DrugRepV_2611	Felbamate	Nervous System	Epilepsy	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.7147317 %)	Approved	27742486
DrugRepV_2615	Zonisamide	Nervous System	Epilepsy	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.7356315 %)	Approved	27742486
DrugRepV_2631	Amitriptyline Hydrochloride	Nervous System	Depressive disorder	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.8631848 %)	Approved	27742486
DrugRepV_2637	Valproate Sodium	Nervous System	Epilepsy	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.9922594 %)	Approved	27742486
DrugRepV_2643	Sumatriptan Succinate	Nervous System	Migraine disorder	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.0465676 %)	Approved, Investigational	27742486
DrugRepV_2682	Levetiracetam	Nervous System	Epilepsy	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.5916963 %)	Approved, Investigational	27742486
DrugRepV_2688	Chlorpromazine	Nervous System	Schizophrenia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.7555603 %)	Approved	27742486
DrugRepV_2733	Phenytoin Sodium	Nervous System	Seizures	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.4867115 %)	Approved, Vet approved	27742486
DrugRepV_2740	Gabapentin Hydrochloride	Nervous System	Epilepsy (seizure)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.614607 %)	Approved	27742486
DrugRepV_2742	Carbamazepine	Nervous System	Epilepsy and pain	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.6723227 %)	Approved	27742486
DrugRepV_2744	Amantadine Hydrochloride	Nervous System	Influenza and Parkinson Disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.6791464 %)	Approved	27742486
DrugRepV_2745	Aripiprazole	Nervous System	Schizophrenia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.7508746 %)	Approved	27742486
DrugRepV_2747	Rivastigmine Tartrate	Nervous System	Dementia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.7832229 %)	Approved, Investigational	27742486
DrugRepV_2749	Gabapentin	Nervous System	Epilepsy (seizure)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.8662068 %)	Approved	27742486
DrugRepV_2750	Bupivacaine Hydrochloride	Nervous System	Anesthesia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.8793995 %)	Approved	27742486
DrugRepV_2757	Risperidone	Nervous System	Schizophrenia | Mood disorders	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.0706996 %)	Approved, Investigational	27742486
DrugRepV_2766	Rufinamide	Nervous System	Seizure disorder :- Lennox-Gastuat syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.2854179 %)	Approved	27742486
DrugRepV_2773	Agomelatine	Nervous System	Depression	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.435983 %)	Approved	27742486
DrugRepV_2781	Betahistine Dihydrochloride	Nervous System	Vertigo assosicated with Ménière's disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.5509946 %)	Approved	27742486
DrugRepV_2785	Bethanechol chloride	Nervous System	Neurogenic bladder dysfunction	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.6656964 %)	Approved	27742486
DrugRepV_2799	Prilocaine	Nervous System	Anesthesia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.9717216 %)	Approved	27742486
DrugRepV_2803	Maprotiline Hydrochloride	Nervous System	Bipolar depression	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.0613707 %)	Approved, Investigational	27742486
DrugRepV_2804	Rasagiline Mesylate	Nervous System	Idiopathic Parkinson's disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.0889023 %)	Approved	27742486
DrugRepV_2807	Varenicline tartrate	Nervous System	Nicotine dependence	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.1953001 %)	Approved	27742486
DrugRepV_2820	Oxcarbazepine	Nervous System	Partial seizures	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.5907524 %)	Approved	27742486
DrugRepV_2821	Pramipexole Dihydrochloride Monohydrate	Nervous System	Parkinson's disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.5989777 %)	Approved, Investigational	27742486
DrugRepV_2826	Medetomidine Hydrochloride	Nervous System	Surgical anesthetic | Analgesic	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.7627474 %)	Approved, Vet approved	27742486
DrugRepV_2828	Paroxetine Hydrochloride	Nervous System	Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.9168009 %)	Approved, Investigational	27742486
DrugRepV_2830	Idebenone	Nervous System	Visual impairment in adolescent and adult patients with Leber’s Hereditary Optic Neuropathy (LHON)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.92252 %)	Approved, Investigational	27742486
DrugRepV_2841	Venlafaxine	Nervous System	Depression | General anxiety disorder | Social phobia | Panic disorder | vasomotor symptoms	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-6.3017038 %)	Approved	27742486
DrugRepV_2846	Divalproex Sodium	Nervous System	Seizures	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-6.5343075 %)	Approved	27742486
DrugRepV_2847	Topiramate	Nervous System	Seizures (Epilepsy) | Migraine	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-6.553453 %)	Approved	27742486
DrugRepV_2858	Zolmitriptan	Nervous System	Migraine with or without auras	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-7.0517546 %)	Approved	27742486
DrugRepV_2887	Melatonin	Nervous System	Jet lag | Insomnia | Shift-work disorder | Circadian rhythm disorders	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-8.4723795 %)	Approved, Nutraceutical, Vet approved	27742486
DrugRepV_2890	Levodopa	Nervous System	Parkinson's disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-8.6262322 %)	Approved	27742486
DrugRepV_2893	Lurasidone Hydrochloride	Nervous System	Schizophrenia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-8.7511975 %)	Approved, Investigational	27742486
DrugRepV_2895	Moclobemide	Nervous System	Depressive disorder | Bipolar disorder	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-8.9210779 %)	Approved, Investigational	27742486
DrugRepV_2903	Lamotrigine	Nervous System	Epilepsy and bipolar disorder	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-9.203636 %)	Approved, Investigational	27742486
DrugRepV_2914	Pramipexole	Nervous System	Parkinson's disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-10.257475 %)	Approved, Investigational	27742486
DrugRepV_2924	Trifluoperazine Dihydrochloride	Nervous System	Schizophrenia and other psychotic disorders	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-11.74809 %)	Approved	27742486
DrugRepV_2928	Paliperidone	Nervous System	Schizophrenia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-12.545451 %)	Approved	27742486
DrugRepV_2929	Biperiden Hydrochloride	Nervous System	Parkinson disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-12.770433 %)	Approved	27742486
DrugRepV_2932	Riluzole	Nervous System	Amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-13.776241 %)	Approved, Investigational	27742486
DrugRepV_2981	Prothipendyl	Nervous System	Dementia | Depression | Schizophrenia | Anxiety Disorders | Psychosomatic Disorders	Chikungunya virus	CHIKV replicon	NA	EGFP assay	Decrease (50 %)	Investigational	22205980
DrugRepV_2990	Prothipendyl	Nervous System	Dementia | Depression | Schizophrenia | Anxiety Disorders | Psychosomatic Disorders	Chikungunya virus	CHIKV replicon	NA	Rluc assay	Decrease (50 %)	Investigational	22205980
DrugRepV_3002	Imipramine	Nervous System	Depression	Chikungunya virus	La Reunion strain	NA	Real-time PCR	Decrease (100 %)	Approved	28600536
DrugRepV_3003	Imipramine	Nervous System	Depression	Chikungunya virus	La Reunion strain	NA	Plaque assay	Decrease (100 %)	Approved	28600536
DrugRepV_3004	Imipramine	Nervous System	Depression	Chikungunya virus	La Reunion strain	NA	Western blot	Decrease (100 %)	Approved	28600536
DrugRepV_3005	Imipramine	Nervous System	Depression	Chikungunya virus	La Reunion strain	NA	Western blot	Decrease (100 %)	Approved	28600536
DrugRepV_3006	Imipramine	Nervous System	Depression	Chikungunya virus	La Reunion strain	NA	Western blot	Decrease (100 %)	Approved	28600536
DrugRepV_3007	Imipramine	Nervous System	Depression	Chikungunya virus	La Reunion strain	NA	Rluc assay	Decrease (1x 103 logs)	Approved	28600536
DrugRepV_3008	Imipramine	Nervous System	Depression	Chikungunya virus	La Reunion strain	NA	Real-time PCR	Decrease (1x 103 logs)	Approved	28600536
DrugRepV_3009	Imipramine	Nervous System	Depression	Zika virus	Pf13	NA	Real-time PCR	Decrease (100 %)	Approved	28600536
DrugRepV_3010	Imipramine	Nervous System	Depression	Zika virus	Pf13	NA	Plaque assay	Decrease (100 %)	Approved	28600536
DrugRepV_3042	Bromocriptine	Nervous System	Parkinson disease	Chikungunya virus	LR2006 OPY1	NA	Luciferase reporter assay	Decrease (50 %)	Approved	26752081
DrugRepV_3047	Bromocriptine	Nervous System	Parkinson disease	Chikungunya virus	LR2006 OPY1	NA	Luciferase reporter assay	Decrease (50 %)	Approved	26752081
DrugRepV_3053	Bromocriptine	Nervous System	Parkinson disease	Chikungunya virus	CHIKV-Rluc	NA	Luciferase reporter assay	Decrease (65 %)	Approved	26752081
DrugRepV_3064	Bromocriptine	Nervous System	Parkinson disease	Chikungunya virus	CHIKV-Rluc	NA	Renilla luciferase assay	No significant effect (3 %)	Approved	26752081
DrugRepV_3078	Bromocriptine	Nervous System	Parkinson disease	Chikungunya virus	CHIKV-Rluc	NA	Plaque assay	No significant effect (No significant effect Log)	Approved	26752081
DrugRepV_3189	Amantadine	Nervous System	Influenza and Parkinson Disease	Influenza virus	A/Aichi/2/68		Plaque assay	Decrease (50 %)	Approved	22028179
DrugRepV_3192	Amantadine	Nervous System	Influenza and Parkinson Disease	Influenza virus	A/Aichi/2/68		Plaque assay	No significant reduction (No significant reduction log)	Approved	22028179
DrugRepV_3195	Amantadine	Nervous System	Influenza and Parkinson Disease	Influenza virus	A/Aichi/2/68		Quantal assay	No significant reduction (No significant reduction log)	Approved	22028179
DrugRepV_3282	Pimozide	Nervous System	Tourette Disorder	Chikungunya virus	NA	NA	Flow cytometry	Decrease (50 %)	Approved	27177310
DrugRepV_3283	Perphenazine	Nervous System	Psychosis | Nausea and vomiting in adults	Chikungunya virus	NA	NA	Flow cytometry	Decrease (50 %)	Approved	27177310
DrugRepV_3296	Pimozide	Nervous System	Tourette Disorder	Influenza virus	NA		Flow cytometry	Decrease (100 %)	Approved	27177310
DrugRepV_3301	Pimozide	Nervous System	Tourette Disorder	Chikungunya virus	NA	NA	Flow cytometry	Decrease (90 %)	Approved	27177310
DrugRepV_3305	Pimozide	Nervous System	Tourette Disorder	Chikungunya virus	NA	NA	Real-time PCR	Decrease (75 %)	Approved	27177310
DrugRepV_3309	Pimozide	Nervous System	Tourette Disorder	Chikungunya virus	NA	NA	Real-time PCR	Decrease (80 %)	Approved	27177310
DrugRepV_3315	Pimozide	Nervous System	Tourette Disorder	Chikungunya virus	C21	NA	Plaque assay	No significant reduction (0.5 Log)	Approved	27177310
DrugRepV_3572	Trifluoperazine	Nervous System	Schizophrenia and other psychotic disorders	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	Approved	30149038
DrugRepV_3573	Clomipramine	Nervous System	Depression, schizophrenia, Tourette disorder	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	Approved	30149038
DrugRepV_3579	Paroxetine	Nervous System	Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD)	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	Approved, Investigational	30149038
DrugRepV_3580	Thioridazine	Nervous System	Schizophrenia | Anxiety disorder	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	Approved, Withdrawn	30149038
DrugRepV_3583	Asenapine	Nervous System	Psychosis	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	Approved	30149038
DrugRepV_3589	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	Approved	30149038
DrugRepV_3623	Benzodiazepine	Nervous System	Obesity, Sleep Apnea, Obstructive, and Disorders of Gallbladder, Biliary Tract and Pancrease.	Rift Valley fever virus	MP12	NA	qRT-PCR	Decrease (50 %)	Approved, Investigational	27654301
DrugRepV_3624	Benzodiazepine	Nervous System	Obesity, Sleep Apnea, Obstructive, and Disorders of Gallbladder, Biliary Tract and Pancrease.	Severe acute respiratory syndrome coronavirus	Toronto-2	NA	qRT-PCR	Decrease (50 %)	Approved, Investigational	27654301
DrugRepV_3625	Benzodiazepine	Nervous System	Obesity, Sleep Apnea, Obstructive, and Disorders of Gallbladder, Biliary Tract and Pancrease.	Influenza virus	Influenza A/California/7/2009		qRT-PCR	Decrease (50 %)	Approved, Investigational	27654301
DrugRepV_3626	Benzodiazepine	Nervous System	Obesity, Sleep Apnea, Obstructive, and Disorders of Gallbladder, Biliary Tract and Pancrease.	Zika virus	Zika-016	NA	qRT-PCR	Decrease (50 %)	Approved, Investigational	27654301
DrugRepV_4027	Gabapentin	NERVOUS SYSTEM	Epilepsy (seizure)	Hendra virus	NA	NA	Immunolabeling assay	Decrease (50 %)	Approved	20668647
DrugRepV_4038	Phenytoin	Nervous System	Seizures	Hendra virus	NA	NA	Immunolabeling assay	Decrease (50 %)	Approved, Vet approved	20668647
DrugRepV_4053	Phenytoin	Nervous System	Seizures	Nipah virus	NA	NA	Immunolabeling assay	Decrease (50 %)	Approved, Vet approved	20668647
DrugRepV_4076	Caffeine	Nervous System	Fatigue, orthostatic hypotension	Hendra virus	NA	NA	Immunolabeling assay	Decrease (50 %)	Approved	20668647
DrugRepV_4084	Caffeine	Nervous System	Fatigue, orthostatic hypotension	Nipah virus	NA	NA	Immunolabeling assay	Decrease (50 %)	Approved	20668647
DrugRepV_4518	Amantadine	Nervous System	Influenza and Parkinson Disease	Influenza virus	NA		NA	Decrease (50 %)	Approved	15200845
DrugRepV_4538	Amantadine	Nervous System	Influenza and Parkinson Disease	Severe acute respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease	Approved	15200845
DrugRepV_4616	Promazine	Nervous System	Psychomotor agitation	Severe acute respiratory syndrome coronavirus	v2163	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved, Vet approved	19853271
DrugRepV_4617	Promazine	Nervous System	Psychomotor agitation	Severe acute respiratory syndrome coronavirus	Urbani	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved, Vet approved	19853271
DrugRepV_4715	Hydroxyzine pamoate	Nervous System	Anxiety | Tension	Middle East respiratory syndrome coronavirus	EMC/2012 strain	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	29795047
DrugRepV_4722	Acetophenazine Maleate	Nervous System	NA	Middle East respiratory syndrome coronavirus	EMC/2012 strain	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	29795047
DrugRepV_4723	Dosulepin Hydrochloride	Nervous System	Psychosis	Middle East respiratory syndrome coronavirus	EMC/2012 strain	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	29795047
DrugRepV_5405	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Lassa virus	Josiah	NA	Luciferase assay	Decrease (50 %)	Approved	30700611
DrugRepV_5406	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Ebola virus	Mayinga	NA	Luciferase assay	Decrease (50 %)	Approved	30700611
DrugRepV_5430	Naltrexone	Nervous System	Alcohol dependence	Influenza virus	A/Puerto Rico/8/34 (PR8)		Plaque reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	31244822
DrugRepV_5434	Naltrexone	Nervous System	Alcohol dependence	Influenza virus	pdm09A/Mexico/InDRE4487/2009		Plaque reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	31244822
DrugRepV_5438	Naltrexone	Nervous System	Alcohol dependence	Influenza virus	A/Victoria/36/2011		Plaque reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	31244822
DrugRepV_5442	Naltrexone	Nervous System	Alcohol dependence	Influenza virus	A/Puerto Rico/8/34 (PR8)		Virus inhibition assay	Decrease (5.3 log)	Approved, Investigational, Vet approved	31244822
DrugRepV_5446	Naltrexone	Nervous System	Alcohol dependence	Influenza virus	pdm09A/Mexico/InDRE4487/2009		Virus inhibition assay	Decrease (6.2 log)	Approved, Investigational, Vet approved	31244822
DrugRepV_5450	Naltrexone	Nervous System	Alcohol dependence	Influenza virus	A/Victoria/36/2011		Virus inhibition assay	Decrease (5.5 log)	Approved, Investigational, Vet approved	31244822
DrugRepV_5518	Pimozide	Nervous System	Tourette Disorder	Lassa virus	NA	NA	Gaussia luciferase (Gluc) Glow assay	Decrease (50 %)	Approved	31786250
DrugRepV_5522	Ziprasidone	Nervous System	Schizophrenia	Lassa virus	NA	NA	Gaussia luciferase (Gluc) Glow assay	Decrease (50 %)	Approved	31786250
DrugRepV_5536	Valproic Acid	Nervous System	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Approved, Investigational	32353859
DrugRepV_5542	Haloperidol	Nervous System	Schizophrenia | Psychotic disorders | Chemotherapy-induced nausea/vomiting	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Approved	32353859
DrugRepV_5543	Entacapone	Nervous System	Parkinson Disease	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Approved	32353859
DrugRepV_5774	Paroxetine Hydrochloride	Nervous System	Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD)	Dengue virus	Singapore isolates		Plaque assay	Decrease (78 %)	NA	25251726
DrugRepV_5781	Loxapine succinate	Nervous System	Schizophrenia	Dengue virus	Singapore isolates		Plaque assay	Decrease (68 %)	Approved	25251726
DrugRepV_5818	Cotinine	Nervous System	Psychosis	Dengue virus	NA		Immunoflourescence assay	Decrease (52.71 %)	Withdrawn	22155902
DrugRepV_5861	Fluoxetine	Nervous System	Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia	Dengue virus	NA		Plaque assay	Decrease (50 %)	Approved, Vet approved	27572397
DrugRepV_5864	Fluoxetine	Nervous System	Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia	Dengue virus	NA		Western blot	Decrease (Decrease Band intensity)	Approved, Vet approved	27572397
DrugRepV_5867	Fluoxetine	Nervous System	Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia	Dengue virus	NA		Real-time PCR	Decrease (4.5 Fold)	Approved, Vet approved	27572397
DrugRepV_5870	Fluoxetine	Nervous System	Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia	Dengue virus	NA		Immunoflourescence assay	Decrease (0 %)	Approved, Vet approved	27572397
DrugRepV_5873	Fluoxetine	Nervous System	Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia	Dengue virus	NA		Real-time PCR	Decrease (<10 Fold)	Approved, Vet approved	27572397
DrugRepV_5876	Fluoxetine	Nervous System	Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia	Dengue virus	NA		Plaque assay	Decrease (2 Fold)	Approved, Vet approved	27572397
DrugRepV_5879	Fluoxetine	Nervous System	Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia	Dengue virus	NA		Real-time PCR	Decrease (> 80 %)	Approved, Vet approved	27572397
DrugRepV_5929	Prochlorperazine	Nervous System	Nausea | Vomiting | Schizophrenia	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease	Approved	25028694
DrugRepV_5930	Prochlorperazine Novamin	Nervous System	Nausea | Vomiting | Schizophrenia	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (50 %)	Approved	25028694
DrugRepV_5931	Prochlorperazine Dimaleate	Nervous System	Nausea | Vomiting | Schizophrenia	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (50 %)	Approved	25028694
DrugRepV_5932	Prochlorperazine Novamin	Nervous System	Nausea | Vomiting | Schizophrenia	Dengue virus	New Guinea C		Western blot	Decrease (100 %)	Approved	25028694
DrugRepV_5933	Prochlorperazine Dimaleate	Nervous System	Nausea | Vomiting | Schizophrenia	Dengue virus	New Guinea C		Western blot	Decrease (100 %)	Approved	25028694
DrugRepV_5934	Prochlorperazine Novamin	Nervous System	Nausea | Vomiting | Schizophrenia	Dengue virus	New Guinea C		Plaque assay	Decrease (2 Fold)	Approved	25028694
DrugRepV_5935	Prochlorperazine Dimaleate	Nervous System	Nausea | Vomiting | Schizophrenia	Dengue virus	New Guinea C		Plaque assay	Decrease (2.5 Fold)	Approved	25028694
DrugRepV_5936	Prochlorperazine Dimaleate	Nervous System	Nausea | Vomiting | Schizophrenia	Dengue virus	New Guinea C		Plaque assay	Decrease (9 Fold)	Approved	25028694
DrugRepV_5937	Prochlorperazine Dimaleate	Nervous System	Nausea | Vomiting | Schizophrenia	Dengue virus	New Guinea C		Plaque assay	Decrease (2 Fold)	Approved	25028694
DrugRepV_5938	Prochlorperazine Dimaleate	Nervous System	Nausea | Vomiting | Schizophrenia	Dengue virus	New Guinea C		Survival assay	Increase	Approved	25028694
DrugRepV_5939	Prochlorperazine Dimaleate	Nervous System	Nausea | Vomiting | Schizophrenia	Dengue virus	New Guinea C		Survival assay	Increase	Approved	25028694
DrugRepV_5940	Prochlorperazine Dimaleate	Nervous System	Nausea | Vomiting | Schizophrenia	Dengue virus	New Guinea C		Survival assay	Increase	Approved	25028694
DrugRepV_5941	Prochlorperazine Novamin	Nervous System	Nausea | Vomiting | Schizophrenia	Dengue virus	New Guinea C		Survival assay	Increase	Approved	25028694
DrugRepV_5942	Prochlorperazine Novamin	Nervous System	Nausea | Vomiting | Schizophrenia	Dengue virus	New Guinea C		Survival assay	Increase	Approved	25028694
DrugRepV_5943	Prochlorperazine Novamin	Nervous System	Nausea | Vomiting | Schizophrenia	Dengue virus	New Guinea C		Survival assay	Increase	Approved	25028694
DrugRepV_5944	Prochlorperazine Novamin	Nervous System	Nausea | Vomiting | Schizophrenia	Dengue virus	New Guinea C		Survival assay	Increase	Approved	25028694
DrugRepV_5945	Prochlorperazine Novamin	Nervous System	Nausea | Vomiting | Schizophrenia	Dengue virus	New Guinea C		Survival assay	Increase	Approved	25028694
DrugRepV_5946	Prochlorperazine Novamin	Nervous System	Nausea | Vomiting | Schizophrenia	Dengue virus	New Guinea C		Plaque assay	Decrease	Approved	25028694
DrugRepV_5947	Prochlorperazine Novamin	Nervous System	Nausea | Vomiting | Schizophrenia	Dengue virus	New Guinea C		Plaque assay	Decrease	Approved	25028694
DrugRepV_6004	Imipramine	Nervous System	Depression	Dengue virus	16681		Real-time PCR	Decrease (100 %)	Approved	28600536
DrugRepV_6005	Imipramine	Nervous System	Depression	Dengue virus	16681		Plaque assay	Decrease (100 %)	Approved	28600536
DrugRepV_6063	Benzodiazepine	Nervous System	Obesity, Sleep Apnea, Obstructive, and Disorders of Gallbladder, Biliary Tract and Pancrease.	Dengue virus	DENV-2 New guinea C		qRT-PCR	Decrease (90 %)	Phase I	27654301
DrugRepV_6188	Bromocriptine	Nervous System	Parkinson disease	Dengue virus	02--20		Plaque assay	Decrease (50 %)	Approved	27181378
DrugRepV_6189	Bromocriptine	Nervous System	Parkinson disease	Dengue virus	16681		Plaque assay	Decrease (50 %)	Approved	27181378
DrugRepV_6190	Bromocriptine	Nervous System	Parkinson disease	Dengue virus	00-40		Plaque assay	Decrease (50 %)	Approved	27181378
DrugRepV_6191	Bromocriptine	Nervous System	Parkinson disease	Dengue virus	09--48		Plaque assay	Decrease (50 %)	Approved	27181378
DrugRepV_6192	Bromocriptine	Nervous System	Parkinson disease	Dengue virus	09--48		Survival assay	No significant effect	Approved	27181378
DrugRepV_6331	Cotinine	Nervous System	Psychosis	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (52.71 %)	Withdrawn	22155902
DrugRepV_6347	Paracetamol	Nervous System	Fever | Minor aches | Pains	Dengue virus	New Guinea C (NGC)		NA	Decrease (100 %)	Approved	26856827
DrugRepV_7095	Imipramine	Nervous System	Depression	West Nile virus	WT		Real-time PCR	Decrease (100 %)	Approved	28600536
DrugRepV_7096	Imipramine	Nervous System	Depression	West Nile virus	WT		Plaque assay	Decrease (100 %)	Approved	28600536
DrugRepV_7099	Bromocriptine	Nervous System	Parkinson disease	Yellow fever virus	17D		Plaque assay	No significant effect (No significant effect Log)	Approved	26752081
DrugRepV_7170	Benzodiazepine	Nervous System	Obesity, Sleep Apnea, Obstructive, and Disorders of Gallbladder, Biliary Tract and Pancrease.	West Nile virus	KERN515 WN02		qRT-PCR	Decrease (50 %)	Phase I	27654301
DrugRepV_7171	Benzodiazepine	Nervous System	Obesity, Sleep Apnea, Obstructive, and Disorders of Gallbladder, Biliary Tract and Pancrease.	Japanese encephalitis virus	SA14		qRT-PCR	Decrease (50 %)	Phase I	27654301
DrugRepV_7172	Benzodiazepine	Nervous System	Obesity, Sleep Apnea, Obstructive, and Disorders of Gallbladder, Biliary Tract and Pancrease.	Yellow fever virus	17D		qRT-PCR	Decrease (50 %)	Phase I	27654301
DrugRepV_7577	Opipramol	Nervous System	Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders.	SARS Coronavirus-2	BavPat1	NA	RT-PCR	Decrease (50 %)	Investigational	32438446
DrugRepV_7578	Opipramol	Nervous System	Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders.	SARS Coronavirus-2	BavPat1	NA	RT-PCR	Decrease (90 %)	Investigational	32438446
DrugRepV_7586	Fluspirilene	Nervous System	Schizophrenia	SARS Coronavirus-2	WA-1 strain - BEI ; NR-52289	NA	Plaque assay / TCID50/ qRT-PCR	Decrease (50 %)	Approved, Investigational	32438446
DrugRepV_7587	Fluspirilene	Nervous System	Schizophrenia	SARS Coronavirus-2	WA-1 strain - BEI ; NR-52289	NA	Plaque assay / TCID50/ qRT-PCR	Decrease (90 %)	Approved, Investigational	32438446
DrugRepV_7590	Clomipramine	Nervous System	Depression, schizophrenia, Tourette disorder	SARS Coronavirus-2	WA-1 strain - BEI ; NR-52287	NA	Plaque assay / TCID50/ qRT-PCR	Decrease (50 %)	Approved	32438446
DrugRepV_7614	Fluphenazine	Nervous System	Psychosis	SARS Coronavirus-2	WA-1 strain - BEI ; NR-52288	NA	Plaque assay / TCID50/ qRT-PCR	Decrease (50 %)	Approved	32438446
DrugRepV_7624	Benztropine	Nervous System	Parkinson disease	SARS Coronavirus-2	WA-1 strain - BEI ; NR-52284	NA	Plaque assay / TCID50/ qRT-PCR	Decrease (50 %)	Approved	32438446
DrugRepV_7677	Clomipramine	Nervous System	Depression, schizophrenia, Tourette disorder	SARS Coronavirus-2		NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	32511355
DrugRepV_7896	Ziprasidone	Nervous System	Schizophrenia	Lassa virus	NA	NA	GLuc assay	Decrease (50 %)	Approved	31786250
DrugRepV_8294	Tolcapone	Nervous System	Parkinson's Disease	Ebola virus	NA	NA	NA	Decrease (50 %)	Approved, Withdrawn	32425892
DrugRepV_8295	Tolcapone	Nervous System	Parkinson's Disease	Ebola virus	NA	NA	NA	Decrease (50 %)	Approved, Withdrawn	32425892
DrugRepV_8296	Tolcapone	Nervous System	Parkinson's Disease	Ebola virus	NA	NA	NA	Decrease (50 %)	Approved, Withdrawn	32425892
DrugRepV_8297	Tolcapone	Nervous System	Parkinson's Disease	Ebola virus	NA	NA	NA	Decrease (50 %)	Approved, Withdrawn	32425892